Flexion Therapeutics Inc
DelistedCIK 1419600fmd_0YC1W7K4XW30D5PB7Z79GE7WBJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2021, 37 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 23 | 73 | 86 |
| Cost of revenue | – | – | – | – | – | – | 0 | 7 | 10 | 19 |
| Gross profit | – | – | – | – | – | – | 0 | 15 | 63 | 66 |
| Research and development | – | 11 | 11 | 18 | 33 | 41 | 51 | 53 | 70 | 54 |
| Selling, general and administrative | – | – | – | – | 13 | 28 | 79 | 121 | 130 | 105 |
| Total operating expenses | – | 15 | 18 | 27 | 46 | 70 | – | – | – | – |
| Operating income | – | (15) | (18) | (27) | (46) | (70) | (130) | (159) | (136) | (93) |
| Interest expense | – | – | 0 | 0 | 1 | 2 | 11 | 16 | 17 | 20 |
| Other non-operating income (expense) | – | 0 | (0) | (0) | (0) | (2) | (8) | (10) | (14) | (20) |
| Income before taxes | – | – | – | – | – | – | – | (170) | (150) | (113) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (170) | (150) | (114) |
| Net income | (11) | (15) | (18) | (27) | (46) | (72) | (137) | (170) | (150) | (114) |
| Net income to common shareholders | – | (15) | (18) | (27) | (46) | – | – | – | – | – |